Antibe Therapeutics Inc.
ATBPF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $11 | $4 | $9 | $7 |
| Short-Term Investments | $14 | $24 | $26 | $32 |
| Receivables | $2 | $2 | $2 | $2 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $2 | $2 | $1 |
| Total Curr. Assets | $28 | $31 | $38 | $42 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $26 | $26 | $0 |
| Intangibles | $26 | $0 | $0 | $26 |
| Long-Term Investments | $0 | $1 | $1 | $1 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $1 | $1 | $1 |
| Total NC Assets | $28 | $29 | $29 | $29 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $56 | $60 | $67 | $71 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $3 | $3 | $4 | $3 |
| Total Curr. Liab. | $3 | $3 | $4 | $3 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $28 | $28 | $28 | $28 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $28 | $28 | $28 | $28 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $30 | $30 | $32 | $30 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $142 | $142 | $142 | $141 |
| Retained Earnings | -$145 | -$141 | -$136 | -$130 |
| AOCI | $0 | $10 | $10 | $10 |
| Other Equity | $30 | $19 | $19 | $19 |
| Total Equity | $26 | $30 | $35 | $40 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $56 | $60 | $67 | $71 |
| Net Debt | -$11 | -$4 | -$9 | -$7 |